Ryan Preblick Biography and Net Worth

CFO of Indivior

Ryan Preblick became CFO in November 2020, after serving as Interim CFO earlier that year. He has held senior roles in our global finance and commercial operations since 2012. His background includes financial leadership at Honeywell International and over a decade at Altria Corporation.

Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond. His approach to finance is grounded in transparency, discipline, and service to the company’s mission.

What is Ryan Preblick's net worth?: The estimated net worth of Ryan Preblick is at least $10.89 million as of June 8th, 2026. Mr. Preblick owns 284,751 shares of Indivior stock worth more than $10,894,573 as of June 10th. This net worth approximation does not reflect any other investments that Mr. Preblick may own. Learn More about Ryan Preblick's net worth.
How do I contact Ryan Preblick?: The corporate mailing address for Mr. Preblick and other Indivior executives is 10710 Midlothian Turnpike, North Chesterfield, VA 23235, United States. Indivior can also be reached via phone at 804-379-1090 and via email at [email protected]. Learn More on Ryan Preblick's contact information.
Has Ryan Preblick been buying or selling shares of Indivior?: Within the last three months, Ryan Preblick has sold $1,357,200.00 in shares of Indivior stock. Most recently, Ryan Preblick sold 36,000 shares of the business's stock in a transaction on Monday, June 8th. The shares were sold at an average price of $37.70, for a transaction totalling $1,357,200.00. Following the completion of the sale, the chief financial officer now directly owns 284,751 shares of the company's stock, valued at $10,735,112.70. Learn More on Ryan Preblick's trading history.
Who are Indivior's active insiders?: Indivior's insider roster includes Keith Humphreys (Director), Stuart Kingsley (Director), Daniel Ninivaggi (Director), Ryan Preblick (CFO), Barbara Ryan (Director), Mark Stejbach (Director), and David Wheadon (Director). Learn More on Indivior's active insiders.
Are insiders buying or selling shares of Indivior?: In the last twelve months, Indivior insiders bought shares 7 times. They purchased a total of 5,842 shares worth more than $203,342.45. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 36,000 shares worth more than $1,357,200.00. The most recent insider tranaction occured on June, 8th when CFO Ryan Preblick sold 36,000 shares worth more than $1,357,200.00. Insiders at Indivior own 0.7% of the company. Learn More about insider trades at Indivior.
Information on this page was last updated on 6/8/2026.

Ryan Preblick Insider Trading History at Indivior

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/8/2026	Sell	36,000	$37.70	$1,357,200.00	284,751

Ryan Preblick Buying and Selling Activity at Indivior

Indivior Company Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Today's Range

Now: $38.60

$37.65

$38.78

50 Day Range

MA: $34.94

$28.78

$40.61

2 Week Range

Now: $38.60

$13.45

$41.00

Volume

46,955 shs

Average Volume

2,252,316 shs

Market Capitalization

$4.71 billion

P/E Ratio

19.81

Dividend Yield

N/A

Beta

0.88